Current Report Filing (8-k)
01 November 2021 - 11:01PM
Edgar (US Regulatory)
0001535955
false
0001535955
2021-11-01
2021-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
November
1, 2021
LIPOCINE
INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 001-36357
Delaware
|
|
99-0370688
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification Number)
|
675
Arapeen Drive, Suite 202
Salt
Lake City, Utah 84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (801) 994-7383
Former
name or former address, if changed since last report: Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class
|
|
Trading Symbol(s)
|
|
Name of each
exchange on which registered
|
Common Stock,
par value $0.0001 per share
|
|
LPCN
|
|
The NASDAQ Stock
Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
November 1, 2021,
the Company issued a press release announcing presentations at American Association for the Study of Liver Diseases (AASLD) The Liver
Meeting® 2021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
Additionally,
the Company is presenting data at The Liver Meeting® 2021 on November 12-15, 2021. The Company’s materials to be included are
filed as Exhibits 99.2, 99.3 and 99.4.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
The
following exhibits are filed with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LIPOCINE
INC.
|
|
|
|
Date:
|
November
1, 2021
|
By:
|
/s/
Mahesh V. Patel
|
|
|
|
Mahesh
V. Patel
|
|
|
|
President
and Chief Executive Officer
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2024 to May 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2023 to May 2024